ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference
Following the presentation, Mr. Enyedy will be joined by other members
of ImmunoGen’s management team for a question-and-answer session at
A webcast of the presentation and question-and-answer session will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation
of antibody-drug conjugates (ADCs) to improve outcomes for cancer
patients. By generating targeted therapies with enhanced anti-tumor
activity and favorable tolerability profiles, we aim to disrupt the
progression of cancer and offer our patients more good days. We call
this our commitment to “target a better now.” Our lead product
candidate, mirvetuximab soravtansine, is in Phase 3 study for folate
receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in
Phase 1b/2 testing in combination regimens. Our novel IGN candidates for
hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including risks related to preclinical and clinical studies, their
timings and results. A review of these risks can be found in ImmunoGen's
Annual Report on Form 10-K for the fiscal year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005046/en/
Source:
For Investors
THRUST Strategic Communications
Chelcie
Lister, 910-777-3049
chelcie@thrustsc.com
or
For
Media
ImmunoGen, Inc.
Courtney O’Konek, 781-895-0600
courtney.okonek@immunogen.com
or
FTI
Consulting Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com